367 related articles for article (PubMed ID: 24824895)
1. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
[TBL] [Abstract][Full Text] [Related]
2. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
[TBL] [Abstract][Full Text] [Related]
3. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.
Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA
J Clin Invest; 2007 Oct; 117(10):2802-11. PubMed ID: 17823658
[TBL] [Abstract][Full Text] [Related]
4. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
5. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
[TBL] [Abstract][Full Text] [Related]
6. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
Dansithong W; Paul S; Comai L; Reddy S
J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic CUG RNA foci are insufficient to elicit key DM1 features.
Dansithong W; Wolf CM; Sarkar P; Paul S; Chiang A; Holt I; Morris GE; Branco D; Sherwood MC; Comai L; Berul CI; Reddy S
PLoS One; 2008; 3(12):e3968. PubMed ID: 19092997
[TBL] [Abstract][Full Text] [Related]
8. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
9. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy.
Orengo JP; Chambon P; Metzger D; Mosier DR; Snipes GJ; Cooper TA
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2646-51. PubMed ID: 18272483
[TBL] [Abstract][Full Text] [Related]
10. DDX6 regulates sequestered nuclear CUG-expanded DMPK-mRNA in dystrophia myotonica type 1.
Pettersson OJ; Aagaard L; Andrejeva D; Thomsen R; Jensen TG; Damgaard CK
Nucleic Acids Res; 2014 Jun; 42(11):7186-200. PubMed ID: 24792155
[TBL] [Abstract][Full Text] [Related]
11. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
12. The hallmarks of myotonic dystrophy type 1 muscle dysfunction.
Ozimski LL; Sabater-Arcis M; Bargiela A; Artero R
Biol Rev Camb Philos Soc; 2021 Apr; 96(2):716-730. PubMed ID: 33269537
[TBL] [Abstract][Full Text] [Related]
13. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.
Koshelev M; Sarma S; Price RE; Wehrens XH; Cooper TA
Hum Mol Genet; 2010 Mar; 19(6):1066-75. PubMed ID: 20051426
[TBL] [Abstract][Full Text] [Related]
14. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation.
Kuyumcu-Martinez NM; Wang GS; Cooper TA
Mol Cell; 2007 Oct; 28(1):68-78. PubMed ID: 17936705
[TBL] [Abstract][Full Text] [Related]
15. Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.
Wang M; Weng WC; Stock L; Lindquist D; Martinez A; Gourdon G; Timchenko N; Snape M; Timchenko L
Mol Cell Biol; 2019 Nov; 39(21):. PubMed ID: 31383751
[TBL] [Abstract][Full Text] [Related]
16. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
17. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel.
Tang ZZ; Yarotskyy V; Wei L; Sobczak K; Nakamori M; Eichinger K; Moxley RT; Dirksen RT; Thornton CA
Hum Mol Genet; 2012 Mar; 21(6):1312-24. PubMed ID: 22140091
[TBL] [Abstract][Full Text] [Related]
18. FISH Protocol for Myotonic Dystrophy Type 1 Cells.
Klein AF; Arandel L; Marie J; Furling D
Methods Mol Biol; 2020; 2056():203-215. PubMed ID: 31586350
[TBL] [Abstract][Full Text] [Related]
19. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts.
Fardaei M; Larkin K; Brook JD; Hamshere MG
Nucleic Acids Res; 2001 Jul; 29(13):2766-71. PubMed ID: 11433021
[TBL] [Abstract][Full Text] [Related]
20. High-throughput kinome-RNAi screen identifies protein kinase R activator (PACT) as a novel genetic modifier of CUG foci integrity in myotonic dystrophy type 1 (DM1).
Neault N; O'Reilly S; Baig AT; Plaza-Diaz J; Azimi M; Farooq F; Baird SD; MacKenzie A
PLoS One; 2021; 16(9):e0256276. PubMed ID: 34520479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
